IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...
IRVING, Texas--(BUSINESS WIRE)-- BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space ...
Image source: The Motley Fool. biote (NASDAQ:BTMD) reported lower total and procedure revenues, attributed to elevated clinic attrition and a voluntary product recall, but offset these pressures with ...
This article first appeared on GuruFocus. Biote Corp (NASDAQ:BTMD) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $47.76 million, and the earnings ...
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in biote Corp.'s (NASDAQ:BTMD) instance, it's good news for shareholders.
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients’ lives by providing hormone replacement therapy and healthy aging solutions, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results